Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration
Meghan D. Morris(University of California, San Francisco), Kimberly Page(University of New Mexico), Andrew R. Lloyd(Oregon Health & Science University), Judith A. Hahn(San Francisco VA Medical Center), Margaret Hellard(The Alfred Hospital), Stephen Shiboski(University of California, San Francisco), Naglaa H. Shoukry(Centre Hospitalier de l’Université de Montréal), Maria Prins(University of Amsterdam), Jason Grebely(UNSW Sydney), Gregory J. Dore(UNSW Sydney), Julie Bruneau(Inserm), Lisa Maher(UNSW Sydney), Andrea L. Cox(Johns Hopkins University), Georg M. Lauer(Broad Institute), Thomas Rice(University of Exeter), Arthur Y. Kim(Harvard University)
Cited by 69
Related Papers
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study
|BMJ|2006|845
Cross-sectional Comparison of the Prevalence of Age-Associated Comorbidities and Their Risk Factors Between HIV-Infected and Uninfected Individuals: The AGEhIV Cohort Study
|Clinical Infectious Diseases|2014|773
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
|The Lancet. Gastroenterology & hepatology|2022|664